Maze Therapeutics Inc (MAZE) reported better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) came in at $-0.66, surpassing Wall Street's consensus estimate of $-0.72 by $0.06. Revenue remained at $0.0B, aligning with expectations.
This update provides insight into Maze Therapeutics' operational performance and financial health. The company, based in South San Francisco, California, is focused on developing novel, small-molecule precision medicines for patients with renal, cardiovascular, and related metabolic diseases. It employs 125 full-time employees and went public on January 31, 2025.
Maze's lead programs, MZE829 and MZE782, utilize its Maze Compass platform to inform all phases of drug discovery and development. MZE829 targets APOL1 kidney disease, while MZE782 focuses on a novel target for chronic kidney disease. The company will host an earnings conference call after market close to discuss these results and provide further insights into its business performance.
Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.